Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial.
Identifieur interne : 000663 ( PubMed/Curation ); précédent : 000662; suivant : 000664Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial.
Auteurs : Radu Constantinescu [États-Unis] ; Jordan Elm ; Peggy Auinger ; Saloni Sharma ; Erika F. Augustine ; Laith Khadim ; Karl KieburtzSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2014.
Descripteurs français
- Wicri :
- geographic : États-Unis.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Cohort Studies, Double-Blind Method, Female, Humans, Incidence, Male, Melanoma (chemically induced), Melanoma (epidemiology), Middle Aged, National Institutes of Health (U.S.), Neuroprotective Agents (therapeutic use), Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Selegiline (therapeutic use), Skin Neoplasms (epidemiology), United States, Young Adult.
- MESH :
- chemical , therapeutic use : Neuroprotective Agents, Selegiline.
- geographic : United States.
- chemically induced : Melanoma.
- drug therapy : Parkinson Disease.
- epidemiology : Melanoma, Parkinson Disease, Skin Neoplasms.
- Adult, Aged, Aged, 80 and over, Cohort Studies, Double-Blind Method, Female, Humans, Incidence, Male, Middle Aged, National Institutes of Health (U.S.), Young Adult.
Abstract
The risk for malignant melanoma is higher than expected in Parkinson's disease (PD). The National Institutes of Health (NIH) Exploratory Trials in PD (NET-PD) Long-term Study 1 (LS-1) trial is a contemporary phase 3 study of subjects with early, treated PD. The objective of this work was to assess the incidence of malignant melanoma in a PD cohort.
DOI: 10.1002/mds.25734
PubMed: 24323565
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000663
Links to Exploration step
pubmed:24323565Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial.</title><author><name sortKey="Constantinescu, Radu" sort="Constantinescu, Radu" uniqKey="Constantinescu R" first="Radu" last="Constantinescu">Radu Constantinescu</name><affiliation wicri:level="1"><nlm:affiliation>Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York</wicri:regionArea></affiliation></author><author><name sortKey="Elm, Jordan" sort="Elm, Jordan" uniqKey="Elm J" first="Jordan" last="Elm">Jordan Elm</name></author><author><name sortKey="Auinger, Peggy" sort="Auinger, Peggy" uniqKey="Auinger P" first="Peggy" last="Auinger">Peggy Auinger</name></author><author><name sortKey="Sharma, Saloni" sort="Sharma, Saloni" uniqKey="Sharma S" first="Saloni" last="Sharma">Saloni Sharma</name></author><author><name sortKey="Augustine, Erika F" sort="Augustine, Erika F" uniqKey="Augustine E" first="Erika F" last="Augustine">Erika F. Augustine</name></author><author><name sortKey="Khadim, Laith" sort="Khadim, Laith" uniqKey="Khadim L" first="Laith" last="Khadim">Laith Khadim</name></author><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24323565</idno><idno type="pmid">24323565</idno><idno type="doi">10.1002/mds.25734</idno><idno type="wicri:Area/PubMed/Corpus">000663</idno><idno type="wicri:Area/PubMed/Curation">000663</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial.</title><author><name sortKey="Constantinescu, Radu" sort="Constantinescu, Radu" uniqKey="Constantinescu R" first="Radu" last="Constantinescu">Radu Constantinescu</name><affiliation wicri:level="1"><nlm:affiliation>Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York</wicri:regionArea></affiliation></author><author><name sortKey="Elm, Jordan" sort="Elm, Jordan" uniqKey="Elm J" first="Jordan" last="Elm">Jordan Elm</name></author><author><name sortKey="Auinger, Peggy" sort="Auinger, Peggy" uniqKey="Auinger P" first="Peggy" last="Auinger">Peggy Auinger</name></author><author><name sortKey="Sharma, Saloni" sort="Sharma, Saloni" uniqKey="Sharma S" first="Saloni" last="Sharma">Saloni Sharma</name></author><author><name sortKey="Augustine, Erika F" sort="Augustine, Erika F" uniqKey="Augustine E" first="Erika F" last="Augustine">Erika F. Augustine</name></author><author><name sortKey="Khadim, Laith" sort="Khadim, Laith" uniqKey="Khadim L" first="Laith" last="Khadim">Laith Khadim</name></author><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Cohort Studies</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Incidence</term><term>Male</term><term>Melanoma (chemically induced)</term><term>Melanoma (epidemiology)</term><term>Middle Aged</term><term>National Institutes of Health (U.S.)</term><term>Neuroprotective Agents (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (epidemiology)</term><term>Selegiline (therapeutic use)</term><term>Skin Neoplasms (epidemiology)</term><term>United States</term><term>Young Adult</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Neuroprotective Agents</term><term>Selegiline</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>United States</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Melanoma</term><term>Parkinson Disease</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Cohort Studies</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Incidence</term><term>Male</term><term>Middle Aged</term><term>National Institutes of Health (U.S.)</term><term>Young Adult</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>États-Unis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The risk for malignant melanoma is higher than expected in Parkinson's disease (PD). The National Institutes of Health (NIH) Exploratory Trials in PD (NET-PD) Long-term Study 1 (LS-1) trial is a contemporary phase 3 study of subjects with early, treated PD. The objective of this work was to assess the incidence of malignant melanoma in a PD cohort.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">24323565</PMID><DateCreated><Year>2014</Year><Month>03</Month><Day>04</Day></DateCreated><DateCompleted><Year>2014</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2015</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial.</ArticleTitle><Pagination><MedlinePgn>263-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.25734</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The risk for malignant melanoma is higher than expected in Parkinson's disease (PD). The National Institutes of Health (NIH) Exploratory Trials in PD (NET-PD) Long-term Study 1 (LS-1) trial is a contemporary phase 3 study of subjects with early, treated PD. The objective of this work was to assess the incidence of malignant melanoma in a PD cohort.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Incident melanoma cases were identified from the adverse events log. The expected number of cases was calculated, using the expected incidence rates and the number of person-years.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 618 females and 1119 males were followed for 6452 person-years; 19 new melanoma cases were observed. The expected number was 5.29. The standardized event ratio compared to the general population was 3.6 (95% confidence interval, 2.2-5.6).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The risk for developing melanoma was higher than expected in the NET-PD LS-1 cohort and was similar to the risk reported in earlier comparable clinical trial cohorts. Dermatologic screening may be useful in Parkinson's disease to identify melanoma at an early stage.</AbstractText><CopyrightInformation>© 2013 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Constantinescu</LastName><ForeName>Radu</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elm</LastName><ForeName>Jordan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Auinger</LastName><ForeName>Peggy</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Saloni</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Augustine</LastName><ForeName>Erika F</ForeName><Initials>EF</Initials></Author><Author ValidYN="Y"><LastName>Khadim</LastName><ForeName>Laith</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Kieburtz</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><CollectiveName>NET-PD Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K12 NS066098</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS043127</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS043128</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01NS043127</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01NS043128</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>12</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>14611-51-9</RegistryNumber><NameOfSubstance UI="D012642">Selegiline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2010 Sep 15;25(12):1801-8</RefSource><PMID Version="1">20669311</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2011 Jun 7;76(23):2002-9</RefSource><PMID Version="1">21646627</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2012;7(9):e45183</RefSource><PMID Version="1">23028833</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2012 Oct;27(12):1513-21</RefSource><PMID Version="1">23079770</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Acad Dermatol. 2013 Jun;68(6):e169-75</RefSource><PMID Version="1">23545369</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Cell Biol. 2000 Dec;12(6):719-24</RefSource><PMID Version="1">11063938</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Apr 15;22(5):720-2</RefSource><PMID Version="1">17373726</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Causes Control. 2010 May;21(5):697-707</RefSource><PMID Version="1">20054708</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015331">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015994">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008545">Melanoma</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009316">National Institutes of Health (U.S.)</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018696">Neuroprotective Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012642">Selegiline</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012878">Skin Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS667265</OtherID><OtherID Source="NLM">PMC4375545</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">malignant melanoma</Keyword><Keyword MajorTopicYN="N">standardized event ratio</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2013</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24323565</ArticleId><ArticleId IdType="doi">10.1002/mds.25734</ArticleId><ArticleId IdType="pmc">PMC4375545</ArticleId><ArticleId IdType="mid">NIHMS667265</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000663 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000663 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:24323565
|texte= Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:24323565" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |